Amgen, Inc.

Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.

ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, replacing Dr. Alan Sandler who will return to the company's Board of Directors.

Samsung Biologics has signed a $1.3 billion production contract with an unnamed US pharmaceutical company, extending through 2029.

Jiangsu Hengrui Pharmaceuticals has licensed its selective myosin blocker HRS-1893 to Delaware-based startup Braveheart Bio for $65 million upfront plus potential milestone payments exceeding $1 billion.

Merck KGaA has appointed David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare business sector, bringing over 20 years of experience and leadership in developing 15 approved drugs worldwide.

Amgen received expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events.

The FDA has expanded Repatha's (evolocumab) indication to include adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL cholesterol, removing the requirement for prior cardiovascular disease diagnosis.

I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.

Royalty Pharma acquired BeOne Medicines' royalty rights to IMDELLTRA (tarlatamab-dlle) for up to $950 million, with $885 million paid upfront and an option for additional $65 million within 12 months.

Johnson & Johnson announced a $55 billion U.S. manufacturing initiative in March 2025, representing 25% more capital allocation to domestic operations than the previous four years.